Superbrewed Food Launches Thryvia Protein-Derived Postbiotic

Superbrewed Food, a company specializing in fermentation-derived ingredients, announced the commercial launch of Thryvia, a protein-derived postbiotic developed to support gut and immune function.

It is shelf-stable, has a low inclusion rate, and its supply is immediately available. Third-party preclinical studies demonstrate that it can selectively activate the pattern-recognition receptors of TLR2, TLR5, and NOD2, which is shown in vivo to support intestinal health and host-response activity.

The company reported that consumers perceived improvements in digestive comfort in a four-week consumer survey.

Because Thryvia is a postbiotic, it doesn’t need to maintain live-organism viability through manufacturing, distribution, and shelf life. The ingredient is flexible across capsules, powders, gummies, bars, foods, and beverages, including shelf-stable and ultra-high temperature processed formats and pet nutrition, with a typical inclusion rate of 200 mg per serving.

“Consumers understand digestive comfort and immune health, but brand owners need differentiated ingredients backed by science that also work in real-world products,” said Bryan Tracy, co-founder and CEO of Superbrewed Food. “Thryvia brings science, differentiated positioning and practical formulation together, giving our customers a clear path to products that stand out.”

In other news, Michael Bush, a long-time nutrition industry executive, has joined Superbrewed Food as co-chairman of the board. Bush previously served as president and CEO of Ganeden, where he helped build and commercialize the company’s probiotic platforms. “As someone who has spent years in the microbiome space, I know exactly what it takes to bring a category-defining ingredient to market, and Thryvia has that potential,” Bush said. “I’m thrilled to work alongside this team to bring fermented ingredients to market that meet real, unmet needs across the food, beverage, supplement, and animal health industries.”

Thryvia is produced from heat-killed Clostridium tyrobutyricum ASM19, and received a “No Questions” letter from the U.S. Food and Drug Administration.